{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:07:37Z","timestamp":1793333257045,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"Objectives<\/jats:title>To illustrate the epidemiologic and cost-effectiveness impact of shifting the focus from population-based screening toward a targeted management approach for genital chlamydia infection.<\/jats:p><\/jats:sec>Design<\/jats:title>Modeling study, implementing an individual-based, stochastic, dynamic network model.<\/jats:p><\/jats:sec>Setting<\/jats:title>Hong Kong.<\/jats:p><\/jats:sec>Population<\/jats:title>A hypothetical sample network of 10,000 people with a partnership distribution based on Hong Kong's sexually active population of reproductive age (age 18\u201349 years).<\/jats:p><\/jats:sec>Interventions<\/jats:title>In this study, we present several scenarios with different implementations of universal vs. targeted screening (based on partner numbers). We also explored the impact of (1) screening only, (2) screening plus expedited partner therapy, and (3) screening plus partner testing.<\/jats:p><\/jats:sec>Primary outcome measures<\/jats:title>Change of chlamydia prevalence before and after implementing the different strategies. The cost-effectiveness analysis reports total direct cost from a health provider perspective, the QALYs gained, and incremental cost-effectiveness ratios (ICER).<\/jats:p><\/jats:sec>Results<\/jats:title>In comparing the effects of universal screening only and targeted screening of the high-risk population, the mean prevalence during the 10th year of intervention was 2.75 \u00b1 0.30% and 2.35 \u00b1 0.21%, respectively (compared with 3.24 \u00b1 0.30% and 3.35 \u00b1 0.21% before the interventions, respectively). The addition of contact tracing to the latter targeted screening scenario reduces the mean prevalence during the 10th year of intervention to 1.48 \u00b1 0.13% (compared with 3.31 \u00b1 0.33% at baseline) in the best-case of testing before treatment and maximal contact-tracing effectiveness (40%). Overall, the most effective scenarios were those for which interventions focused on the high-risk population defined by the number of partners, with contact tracing included. The ICER for targeted screening with contact tracing at 20% and 40% efficiency was $4,634 and $7,219 per QALY gained, respectively (10-year time horizon). Expedited partner therapy did not significantly impact overall chlamydia prevalence and caused overtreatment.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Our study suggests that targeted screening with strengthened contact tracing efforts is the most cost-effective strategy to reduce the prevalence of chlamydia in Hong Kong.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.932096","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T07:15:56Z","timestamp":1658906156000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating the impact and cost-effectiveness of chlamydia management strategies in Hong Kong: A modeling study"],"prefix":"10.3389","volume":"10","author":[{"given":"Sandra","family":"Montes-Olivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaz","family":"Ozten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Homer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Fairley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane S.","family":"Hocking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Verschueren van Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C. W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/S1473-3099(17)30310-9","article-title":"Sexually transmitted infections: challenges ahead","volume":"17","author":"Unemo","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"531073","DOI":"10.3389\/fpubh.2021.531073","article-title":"Chlamydia trachomatis screening and treatment in pregnancy to reduce adverse pregnancy and neonatal outcomes: a review","volume":"9","author":"Adachi","year":"2021","journal-title":"Front Public Health"},{"key":"B3","article-title":"Wellcome Trust\u2013Funded Monographs and Book Chapters. Chlamydia: A Disease without a History","volume-title":"The Hidden Affliction: Sexually Transmitted Infections and Infertility in History","author":"Worboys","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD010866","DOI":"10.1002\/14651858.CD010866.pub2","article-title":"Screening for genital chlamydia infection","volume":"9","author":"Low","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"c1642","DOI":"10.1136\/bmj.c1642","article-title":"Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial","volume":"340","author":"Oakeshott","year":"2010","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(18)31816-6","article-title":"Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial","volume":"392","author":"Hocking","year":"2018","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/sextrans-2021-054992","article-title":"Where to go to in chlamydia control? From infection control towards infectious disease control","volume":"97","author":"van Bergen","year":"2021","journal-title":"Sex Transm Infect."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.2147\/IDR.S219755","article-title":"Shigella: antibiotic-resistance mechanisms and new horizons for treatment","volume":"12","author":"Ranjbar","year":"2019","journal-title":"Infect Drug Resist."},{"key":"B9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12879-017-2635-y","article-title":"Retesting and repeat positivity following diagnosis of Chlamydia trachomatis and Neisseria gonorrhoea in New Zealand: a retrospective cohort study","volume":"17","author":"Rose","year":"2017","journal-title":"BMC Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0172561","DOI":"10.1371\/journal.pone.0172561","article-title":"Prevalence and risk factors of chlamydia infection in Hong Kong: a population-based geospatial household survey and testing","volume":"12","author":"Wong","year":"2017","journal-title":"PLoS ONE"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.3390\/ijerph18084032","article-title":"De-sexualizing partner notification: a qualitative study on chinese young adults with chlamydia","volume":"18","author":"Lau","year":"2021","journal-title":"Int J Environ Res Public Health."},{"key":"B12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1071\/SH18235","article-title":"Agent-based modelling study of antimicrobial-resistant Neisseria gonorrhoeae transmission in men who have sex with men: towards individualised diagnosis and treatment","volume":"16","author":"Zienkiewicz","year":"2019","journal-title":"Sex Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00007435-200406000-00012","article-title":"Scale-free networks and sexually transmitted diseases: a description of observed patterns of sexual contacts in Britain and Zimbabwe","volume":"31","author":"Schneeberger","year":"2004","journal-title":"Sex Transm Dis."},{"key":"B14","year":"2017","journal-title":"The Report of Youth Sexuality Study 2016: The Family Planning Association of Hong Kong"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1086\/652402","article-title":"Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies","volume":"201","author":"Geisler","year":"2010","journal-title":"J Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1258\/0956462021924712","article-title":"What proportion of episodes of gonorrhoea and chlamydia becomes symptomatic?","volume":"13","author":"Korenromp","year":"2002","journal-title":"Int J STD AIDS"},{"key":"B17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00007435-199704000-00008","article-title":"3rd. Spontaneous clearance of Chlamydia trachomatis infection in untreated patients","volume":"24","author":"Parks","year":"1997","journal-title":"Sex Transm Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/OLQ.0b013e318151497d","article-title":"3rd. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment","volume":"35","author":"Geisler","year":"2008","journal-title":"Sex Transm Dis."},{"key":"B19","unstructured":"Population estimates: Population by sex and age group, Hong Kong2021"},{"key":"B20","first-page":"273","article-title":"Primary care of patients with sexually transmitted diseases or genitourinary symptoms in Hong Kong","volume":"11","author":"Wong","year":"2005","journal-title":"Hong Kong Med J."},{"key":"B21","unstructured":"Fees and Charges for Public Health Care Services provided by the Department of Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"c7250","DOI":"10.1136\/bmj.c7250","article-title":"Costs and cost effectiveness of different strategies for chlamydia screening and partner notification: an economic and mathematical modelling study","volume":"342","author":"Turner","year":"2011","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2006.024364","article-title":"The cost effectiveness of opportunistic chlamydia screening in England","author":"Adams","year":"2007","journal-title":"Sex Transm Infect."},{"key":"B24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jval.2013.10.005","article-title":"Valuing the health states associated with Chlamydia trachomatis infections and their sequelae: a systematic review of economic evaluations and primary studies","volume":"17","author":"Jackson","year":"2014","journal-title":"Value Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/sextrans-2016-052597","article-title":"Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all?","volume":"93","author":"Ong","year":"2017","journal-title":"Sex Transm Infect"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta14070","article-title":"The effectiveness and cost-effectiveness of behavioural interventions for the prevention of sexually transmitted infections in young people aged 13-19: a systematic review and economic evaluation","volume":"14","author":"Shepherd","year":"2010","journal-title":"Health Technol Assess"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1086\/652395","article-title":"Risk of sequelae after Chlamydia trachomatis genital infection in women","volume":"201","author":"Haggerty","year":"2010","journal-title":"J Infect Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/OLQ.0000000000001357","article-title":"The estimated lifetime medical cost of chlamydia, gonorrhea, and trichomoniasis in the United States, 2018","volume":"48","author":"Kumar","year":"2021","journal-title":"Sex Transm Dis."},{"key":"B29","article-title":"The National Academies Collection: Reports funded by National Institutes of Health","volume-title":"Vaccines for the 21st Century: A Tool for Decisionmaking","author":"Stratton","year":"2000"},{"key":"B30","unstructured":"World Development Indicators: GDP per capita: World Bank national accounts data, and OECD National Accounts data files2021"},{"key":"B31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40273-020-00914-6","article-title":"Calculating and interpreting ICERs and Net Benefit","volume":"38","author":"Paulden","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"B32","unstructured":"National Chlamydia Screening Programme"},{"key":"B33","unstructured":"Chlamydia and Gonorrhoea: Screening"},{"key":"B34","unstructured":""},{"key":"B35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13643-021-01658-w","article-title":"Screening for chlamydia and\/or gonorrhea in primary health care: systematic reviews on effectiveness and patient preferences","volume":"10","author":"Pillay","year":"2021","journal-title":"Syst Rev."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3815107","article-title":"Preferences for chlamydia testing and management in Hong Kong: a discrete choice experiment","author":"Ong","year":"2021","journal-title":"Sex Transm Infect."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4386127","DOI":"10.1155\/2016\/4386127","article-title":"A Systematic Review of Point of Care Testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis","volume":"2016","author":"Herbst de Cortina","year":"2016","journal-title":"Infect Dis Obstet Gynecol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1177\/0956462417736431","article-title":"Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits","volume":"29","author":"Whitlock","year":"2018","journal-title":"Int J STD AIDS."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0212420","DOI":"10.1371\/journal.pone.0212420","article-title":"Online testing for sexually transmitted infections: A whole systems approach to predicting value","volume":"14","author":"Turner","year":"2019","journal-title":"PLoS ONE"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1186\/1471-2458-13-1040","article-title":"Outreach for chlamydia and gonorrhoea screening: a systematic review of strategies and outcomes","volume":"13","author":"Hengel","year":"2013","journal-title":"BMC Public Health"},{"key":"B41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/OLQ.0000000000000095","article-title":"Chlamydia screening strategies and outcomes in educational settings: a systematic review","volume":"41","author":"Jamil","year":"2014","journal-title":"Sex Transm Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1001777","DOI":"10.1371\/journal.pmed.1001777","article-title":"Uptake and population-level impact of expedited partner therapy (EPT) on Chlamydia trachomatis and Neisseria gonorrhoeae: the Washington State community-level randomised trial of EPT","volume":"12","author":"Golden","year":"2015","journal-title":"PLoS Med."},{"key":"B43","unstructured":"Australasian Contact Tracing Guidelines"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41467-019-11216-7","article-title":"Genomic epidemiology of syphilis reveals independent emergence of macrolide resistance across multiple circulating lineages","volume":"10","author":"Beale","year":"2019","journal-title":"Nat Commun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"100779","DOI":"10.1016\/j.eclinm.2021.100779","article-title":"Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: a mathematical model","volume":"33","author":"Ong","year":"2021","journal-title":"EClinical Med."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.932096\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T07:16:02Z","timestamp":1658906162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.932096\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":45,"alternative-id":["10.3389\/fpubh.2022.932096"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.932096","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"article-number":"932096"}}